• 1. Synthesis, biological evaluation and molecular modeling of urea-containing MraY inhibitors
  Martin Oliver,Laurent Le Corre,Mélanie Poinsot,Alessandra Corio,Léa Madegard,Micha?l Bosco,Ana Amoroso,Bernard Joris,Rodolphe Auger,Thierry Touzé,Ahmed Bouhss,Sandrine Calvet-Vitale,Christine Gravier-Pelletier Org. Biomol. Chem. 2021 19 5844

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Pyridinylpiperazines

Research Brief on 1-[5-(Trifluoromethyl)pyridin-2-yl]piperazine (CAS: 132834-58-3): Recent Advances and Applications

1-[5-(Trifluoromethyl)pyridin-2-yl]piperazine (CAS: 132834-58-3) is a piperazine derivative with significant potential in medicinal chemistry and drug discovery. This compound, characterized by its trifluoromethylpyridine moiety, has garnered attention due to its versatile pharmacological properties and its role as a key intermediate in the synthesis of bioactive molecules. Recent studies have explored its applications in central nervous system (CNS) disorders, oncology, and infectious diseases, highlighting its importance in contemporary pharmaceutical research.

In the context of CNS disorders, 1-[5-(trifluoromethyl)pyridin-2-yl]piperazine has been investigated as a scaffold for developing novel serotonin and dopamine receptor modulators. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in enhancing receptor binding affinity when incorporated into selective serotonin reuptake inhibitors (SSRIs). The trifluoromethyl group was found to improve metabolic stability and blood-brain barrier penetration, making it a promising candidate for treating depression and anxiety disorders.

Oncology research has also leveraged this compound for its potential in targeted cancer therapies. A recent preclinical study highlighted its role in inhibiting protein kinases involved in tumor proliferation. The compound's ability to act as a hinge-binding motif in kinase inhibitors was validated through crystallographic analysis, revealing its interaction with ATP-binding sites. These findings, published in Bioorganic & Medicinal Chemistry Letters, suggest its utility in designing next-generation kinase inhibitors for cancers such as non-small cell lung carcinoma (NSCLC).

Infectious disease research has identified 1-[5-(trifluoromethyl)pyridin-2-yl]piperazine as a key component in antimalarial and antibacterial agents. A 2024 study in Antimicrobial Agents and Chemotherapy reported its incorporation into hybrid molecules that exhibit dual activity against Plasmodium falciparum and drug-resistant bacterial strains. The trifluoromethyl group was critical in enhancing lipophilicity and bioavailability, addressing challenges associated with existing therapeutics.

Synthetic methodologies for 1-[5-(trifluoromethyl)pyridin-2-yl]piperazine have also advanced, with recent innovations focusing on green chemistry approaches. A 2023 publication in Organic Process Research & Development described a solvent-free catalytic process that improves yield and reduces environmental impact. This development is particularly relevant for industrial-scale production, aligning with the pharmaceutical industry's sustainability goals.

In conclusion, 1-[5-(trifluoromethyl)pyridin-2-yl]piperazine (CAS: 132834-58-3) continues to be a molecule of significant interest across multiple therapeutic areas. Its structural versatility, combined with recent advancements in synthetic and pharmacological research, positions it as a valuable tool for drug discovery. Future studies are expected to explore its applications in precision medicine and combination therapies, further expanding its potential impact on global health.

• 306934-70-3(1-[5-(trifluoromethyl)pyridin-2-yl]-1,4-diazepane)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)